Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of subcutaneous efgartigimod PH20 in CIDP
MOH_2020-03-12_008768Phase 2Not yet recruiting
- Sponsor
- argenx
- Start
- Feb 2020
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa and ENHANZE in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by argenx. Primary endpoints: Long-term safety and tolerability and Long-term treatment effect and efficacy. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
efgartigimod alfaENHANZE
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on MOH_2020-03-12_008768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-12_008768.